These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20392114)

  • 1. Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.
    Ballatore C; Brunden KR; Piscitelli F; James MJ; Crowe A; Yao Y; Hyde E; Trojanowski JQ; Lee VM; Smith AB
    J Med Chem; 2010 May; 53(9):3739-47. PubMed ID: 20392114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening.
    Crowe A; Huang W; Ballatore C; Johnson RL; Hogan AM; Huang R; Wichterman J; McCoy J; Huryn D; Auld DS; Smith AB; Inglese J; Trojanowski JQ; Austin CP; Brunden KR; Lee VM
    Biochemistry; 2009 Aug; 48(32):7732-45. PubMed ID: 19580328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties.
    Ballatore C; Crowe A; Piscitelli F; James M; Lou K; Rossidivito G; Yao Y; Trojanowski JQ; Lee VM; Brunden KR; Smith AB
    Bioorg Med Chem; 2012 Jul; 20(14):4451-61. PubMed ID: 22717239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
    Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
    J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
    Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR
    J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.
    Brunden KR; Yao Y; Potuzak JS; Ferrer NI; Ballatore C; James MJ; Hogan AM; Trojanowski JQ; Smith AB; Lee VM
    Pharmacol Res; 2011 Apr; 63(4):341-51. PubMed ID: 21163349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
    Lou K; Yao Y; Hoye AT; James MJ; Cornec AS; Hyde E; Gay B; Lee VM; Trojanowski JQ; Smith AB; Brunden KR; Ballatore C
    J Med Chem; 2014 Jul; 57(14):6116-27. PubMed ID: 24992153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
    Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
    Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.
    Ballatore C; Brunden KR; Trojanowski JQ; Lee VM; Smith AB; Huryn DM
    Curr Top Med Chem; 2011; 11(3):317-30. PubMed ID: 21320060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
    Brunden KR; Ballatore C; Lee VM; Smith AB; Trojanowski JQ
    Biochem Soc Trans; 2012 Aug; 40(4):661-6. PubMed ID: 22817712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau.
    Li W; Sperry JB; Crowe A; Trojanowski JQ; Smith AB; Lee VM
    J Neurochem; 2009 Aug; 110(4):1339-51. PubMed ID: 19549281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alpha-tocopherol on an animal model of tauopathies.
    Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S
    Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies.
    Pickhardt M; Neumann T; Schwizer D; Callaway K; Vendruscolo M; Schenk D; St George-Hyslop P; Mandelkow EM; Dobson CM; McConlogue L; Mandelkow E; Tóth G
    Curr Alzheimer Res; 2015; 12(9):814-28. PubMed ID: 26510979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further understanding of tau phosphorylation: implications for therapy.
    Medina M; Avila J
    Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
    Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
    Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
    Wolfe MS
    IDrugs; 2010 Dec; 13(12):828-9. PubMed ID: 21154135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N; Suárez-Calvet M; Lleó A
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
    Brunden KR; Trojanowski JQ; Lee VM
    Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.